Sep 2026· Cancer Medicine· Vol 15· 0 citations· 21 references
Medicine
TL;DR
This retrospective observational cohort study assessed biomarker testing and guideline‐concordant matched first‐line therapy use and evaluated their associations with overall survival, diagnosis‐to‐treatment intervals, and 6‐month physical functioning in patients with advanced solid tumors.
Abstract
Biomarker testing and matched therapies are central to precision oncology, but their real‐world uptake and clinical impact among older adults with advanced solid tumors remain poorly characterized. This retrospective observational cohort study assessed biomarker testing and guideline‐concordant matched first‐line therapy use and evaluated their associations with overall survival, diagnosis‐to‐treatment intervals, and 6‐month physical functioning in these patients.
TFE3‐rearranged renal cell carcinoma (TFE3‐rRCC) is uncommon and encompasses biologically diverse tumors, while evidence to guide systemic treatment remains sparse. We examined clinical outcomes, treatment patterns, and molecular features in a multicenter real‐world cohort.
Shu-Xuan Zhu, Si-Qi Zhou, Xi Tian et al.· Cancer Medicine· 0 citations
Glioblastoma (GBM) remains highly morbid despite maximal safe resection, radiotherapy, and chemotherapy, prompting the expansion of clinical investigation. This review examines 4 emerging therapeutic strategies for newly diagnosed and recurrent GBM that address major biological barriers to treatment: tumor immunosuppre...
Deveney Franklin, D. Higgins· Hematology/Oncology Clinics...· 0 citations
Evidence is accumulating to support feasibility and survival benefit in patients treated with matched therapy, and the incorporation of molecular targeted therapies and immunotherapy into the perioperative setting requires clinicians to understand the role of the MTB.
Yu Fujiwara, S. Kato, R. Kurzrock· Hematology/Oncology Clinics...· 0 citations
This news section offers
Cancer
readers timely information on events, public policy analysis, and topical issues. In this issue, the FDA approves a test that enables the identification of patients who are positive for ctDNA and can benefit from adjuvant atezolizumab after cystectomy. In addition, the HERMES trial s...
Adding a third drug to standard immunotherapy combinations can prolong disease control but has not yet improved survival benefit and, when used empirically, increases toxicity. The priority now is validated biomarkers for patient selection and mechanistically distinct therapies, rather than more unselected triplets.
J. Molina-Cerrillo, V. G. dos Santos, T. Alonso-Gordoa· European Urology Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
